Novo Nordisk A/S, member of the Supervisory Board since 2007, appointed Marcus Schindler as its representative to serve on our Supervisory Board in 2018.
Mr Schindler is Senior Vice President and Head of Global Drug Discovery at Novo Nordisk A/S. He is accountable for all of Novo Nordisk’s Research activities across all of NN’s Therapeutic Areas (Diabetes, Obesity, NASH, Chronic Kidney and Cardiovascular Disease and Hemophilia). In addition, he is responsible for identifying, establishing and maintaining all external deals and collaborations up to and including Clinical Proof of Concept within all therapy areas.
Prior to this occupation, Mr Schindler was VP, Head of the Cardiovascular & Metabolic Diseases Innovative Medicines Unit of Astra Zeneca. Previously he was Head of Research for (OSI) Prosidion, based in Oxford, UK, and has held senior positions at Boehringer Ingelheim Pharma and at Glaxo Wellcome’s blue skies research institute, “Glaxo Institute of Applied Pharmacology”, Cambridge, UK.
Mr Schindler received his PhD in Pharmacology from the University of Cambridge and holds a position as adjunct Professor of Pharmacology at the University of Gothenburg. He as co-/authored 50+ peer-reviewed research papers and is an inventor of 25 international patent applications.